Novartis Investor Presentation
New Novartis: Our strategy
Our focus
Our priorities
> Conclusion
Abbreviations
Sandoz is uniquely positioned with a strong and balanced presence
in both Generics and Biosimilars
Gross sales in global Biosimilars and Generics¹
%, vs. key competitors
Illustrative
European "pure-play" Generics
and Biosimilar market leader
H1 sales - total USD 4.7bn (+6%)¹
Accelerating leadership in Europe
Healthcare peers
with Biosimilars sales
% CC
D
C
Sales percentage in
sales¹
Global Biosimilars
<30%
Generics peers
A
E
LLI
B
H
LL
F
Sandoz
Europe
USD 2.5bn
(+7%)
<30%
Double-digit
growth Row
ROW
USD 1.3bn
(+11%)
US
USD 0.9bn
(-2%)
Stabilizing
in US
Sales percentage in Global Gx sales¹
Substantial synergies between Gx and Biosimilars:
commercial execution, channels, people and culture
1. Reported H1'22 Earnings
32
Novartis Investor Presentation | September 22, 2022
U |
NOVARTIS | Reimagining MedicineView entire presentation